Current Report Filing (8-k)
January 18 2022 - 8:17AM
Edgar (US Regulatory)
0001739426
false
12/31
Osmotica Pharmaceuticals plc
00-0000000
0001739426
2022-01-14
2022-01-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 14, 2022
RVL Pharmaceuticals plc
(Exact name of registrant as specified in its charter)
Ireland
|
|
001-38709
|
|
Not Applicable
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
400
Crossing Boulevard
Bridgewater, NJ
|
|
08807
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrant’s telephone number, including
area code): (908) 809-1300
Osmotica Pharmaceuticals plc
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Ordinary Shares
|
RVLP
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
Following the extraordinary general meeting of shareholders (the “Extraordinary
General Meeting”) of RVL Pharmaceuticals plc, formerly Osmotica Pharmaceuticals plc (the “Company”), held on January
14, 2022, the results of which are summarized in Item 5.07 below, the Company has applied for, and received, a Certificate of Registration
on Change of Name (the “Name Change Certificate”) from the Irish Companies Registration Office. The Name Change Certificate
changed the name of the Company from “Osmotica Pharmaceuticals plc” to “RVL Pharmaceuticals plc”, effective as
of January 17, 2022. Consequent amendments to the Company’s Constitution, reflecting the name change, have been made and filed with
the Irish Companies Registration Office (the “Constitution Amendment”).
The foregoing summary description of the Constitution Amendment is
qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 3.1 and is incorporated herein by
reference.
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
At the Extraordinary
General Meeting, the Company’s shareholders approved the proposal to change the Company’s name from Osmotica Pharmaceuticals
plc to RVL Pharmaceuticals plc, based on the following votes:
For
|
|
Against
|
|
Abstain
|
47,809,014
|
|
1,635,376
|
|
60,268
|
In connection with the Company’s name
change, the Company’s ordinary shares will continue trading on the Nasdaq Global Select Market under the new ticker symbol, RVLP,
effective January 19, 2022. The Company’s CUSIP number will not change.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RVL PHARMACEUTICALS PLC
|
|
|
|
Dated: January 18, 2022
|
By:
|
/s/ Brian Markison
|
|
|
Brian Markison
Chief Executive Officer
|
Osmotica Pharmaceuticals (NASDAQ:OSMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Osmotica Pharmaceuticals (NASDAQ:OSMT)
Historical Stock Chart
From Apr 2023 to Apr 2024